Cell Proliferation, Cell Cycle Abnormalities, and Cancer Outcome in Patients with Barrett's Esophagus: A Long-term Prospective Study

Purpose: Elevated cellular proliferation and cell cycle abnormalities, which have been associated with premalignant lesions, may be caused by inactivation of tumor suppressor genes. We measured proliferative and cell cycle fractions of biopsies from a cohort of patients with Barrett's esophagus to better understand the role of proliferation in early neoplastic progression and the association between cell cycle dysregulation and tumor suppressor gene inactivation. Experimental Design: Cell proliferative fractions (determined by Ki67/DNA multiparameter flow cytometry) and cell cycle fractions (DNA content flow cytometry) were measured in 853 diploid biopsies from 362 patients with Barrett's esophagus. The inactivation status of CDKN2A and TP53 was assessed in a subset of these biopsies in a cross-sectional study. A prospective study followed 276 of the patients without detectable aneuploidy for an average of 6.3 years with esophageal adenocarcinoma as an end point. Results: Diploid S and 4N (G2/tetraploid) fractions were significantly higher in biopsies with TP53 mutation and loss of heterozygosity. CDKN2A inactivation was not associated with higher Ki67-positive, diploid S, G1, or 4N fractions. High Ki67-positive and G1-phase fractions were not associated with the future development of esophageal adenocarcinoma (P = 0.13 and P = 0.15, respectively), whereas high diploid S-phase and 4N fractions were (P = 0.03 and P < 0.0001, respectively). Conclusions: High Ki67-positive proliferative fractions were not associated with inactivation of CDKN2A and TP53 or future development of cancer in our cohort of patients with Barrett's esophagus. Biallelic inactivation of TP53 was associated with elevated 4N fractions, which have been associated with the future development of esophageal adenocarcinoma.

[1]  Carissa A. Sanchez,et al.  Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. , 1996, Oncogene.

[2]  Robert Walgate,et al.  Proliferation , 1985, Nature.

[3]  V. Save,et al.  Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  M S Pepe,et al.  Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. , 1994, Statistics in medicine.

[5]  Carissa A. Sanchez,et al.  Selectively Advantageous Mutations and Hitchhikers in Neoplasms , 2004, Cancer Research.

[6]  M. Berenson,et al.  Cell proliferation in esophageal columnar epithelium (Barrett's esophagus). , 1978, Gastroenterology.

[7]  C. Purdie,et al.  Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. , 1993, Oncogene.

[8]  Patricia L. Blount,et al.  p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. , 2001, Cancer research.

[9]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[10]  Carissa A. Sanchez,et al.  Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. , 2000, Journal of the National Cancer Institute.

[11]  R. Schimke,et al.  Differences in mitotic control among mammalian cells. , 1991, Cold Spring Harbor symposia on quantitative biology.

[12]  E. Kuipers,et al.  Epithelial Cell Proliferative Activity of Barrett's Esophagus (Methodology and Correlation with Traditional Cancer Risk Markers) , 1998, Digestive Diseases and Sciences.

[13]  Carissa A. Sanchez,et al.  Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. , 2005, The Lancet. Oncology.

[14]  Formation of the tetraploid intermediate is associated with the development of cells with more than four centrioles in the elastase-simian virus 40 tumor antigen transgenic mouse model of pancreatic cancer. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Carissa A. Sanchez,et al.  Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression , 2001, American Journal of Gastroenterology.

[16]  L. Hartwell,et al.  Genetic control of the cell division cycle in yeast. , 1974, Science.

[17]  T. Louis,et al.  Colorectal epithelial cell proliferative kinetics and risk factors for colon cancer in sporadic adenoma patients. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  S. Shackney,et al.  Model for the genetic evolution of human solid tumors. , 1989, Cancer research.

[19]  G. Eastwood,et al.  Cell proliferation in three types of Barrett's epithelium 1 , 1980, Gut.

[20]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Carissa A. Sanchez,et al.  p53-mutant clones and field effects in Barrett's esophagus. , 1999, Cancer research.

[22]  M. Buyse,et al.  Cell kinetic indicators of premalignant stages of colorectal cancer , 1985, Cancer.

[23]  Carissa A. Sanchez,et al.  Biologic Properties of Columnar Epithelium Underneath Reepithelialized Squamous Mucosa in Barrett's Esophagus , 2005, The American journal of surgical pathology.

[24]  B. Reid,et al.  Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. , 1987, Gastroenterology.

[25]  C. Sotiriou,et al.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.

[26]  C. Sherr,et al.  Principles of Tumor Suppression , 2004, Cell.

[27]  Carissa A. Sanchez,et al.  Crypt Dysplasia With Surface Maturation: A Clinical, Pathologic, and Molecular Study of a Barrett's Esophagus Cohort , 2006, The American journal of surgical pathology.

[28]  C. Cox,et al.  Guidelines for the implementation of clinical DNA cytometry , 2004, Breast Cancer Research and Treatment.

[29]  M. Barrett,et al.  Genotypic analysis of multiple loci in somatic cells by whole genome amplification. , 1995, Nucleic acids research.

[30]  Carissa A. Sanchez,et al.  Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. , 1993, Gastroenterology.

[31]  M. Barrett,et al.  Molecular phenotype of spontaneously arising 4N (G2-tetraploid) intermediates of neoplastic progression in Barrett's esophagus. , 2003, Cancer research.

[32]  D. Pellman,et al.  Limiting the Proliferation of Polyploid Cells , 2007, Cell.

[33]  L. Lovat,et al.  Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis. , 2004, Neoplasia.

[34]  D. Lane,et al.  Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. , 1992, Gastroenterology.

[35]  Patricia L. Blount,et al.  Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables , 2001, American Journal of Gastroenterology.

[36]  C. Maley,et al.  Genetic Mechanisms of TP53 Loss of Heterozygosity in Barrett's Esophagus: Implications for Biomarker Validation , 2006, Cancer Epidemiology Biomarkers & Prevention.

[37]  L. Lovat,et al.  Cyclin A Immunocytology as a Risk Stratification Tool for Barrett's Esophagus Surveillance , 2006, Clinical Cancer Research.

[38]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[39]  T. Tosteson,et al.  Rectal mucosal proliferation and risk of colorectal adenomas: results from a randomized controlled trial. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[40]  M. Pike,et al.  Increased cell division as a cause of human cancer. , 1990, Cancer research.

[41]  E. Kuipers,et al.  Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus. , 2008, Cancer biomarkers : section A of Disease markers.

[42]  S. Vowler,et al.  Effect of Acid Suppression on Molecular Predictors for Esophageal Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[43]  S. Steinberg,et al.  Expansion of the Ki‐67 proliferative compartment correlates with degree of Dysplasia in Barrett's esophagus , 1995, Cancer.

[44]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[45]  Kamran Ayub,et al.  NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma , 2007, PLoS medicine.

[46]  J. Gerdes.  Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. , 1990, Seminars in cancer biology.

[47]  N. Sharpless,et al.  INK4a/ARF: a multifunctional tumor suppressor locus. , 2005, Mutation research.

[48]  G. Wahl,et al.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.

[49]  H. Barr,et al.  Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base , 2006, BMJ : British Medical Journal.

[50]  Carissa A. Sanchez,et al.  A p53-dependent mouse spindle checkpoint , 1995, Science.

[51]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[52]  Gary Longton,et al.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets , 2000, American Journal of Gastroenterology.

[53]  P. Nurse,et al.  Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2 , 1987, Nature.

[54]  Carissa A. Sanchez,et al.  17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. , 1994, Cancer research.

[55]  Carissa A. Sanchez,et al.  Evolution of neoplastic cell lineages in Barrett oesophagus , 1999, Nature Genetics.

[56]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[57]  K. Abrams,et al.  Meta analysis: cancer risk in Barrett’s oesophagus , 2007, Alimentary pharmacology & therapeutics.

[58]  Carissa A. Sanchez,et al.  17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[59]  H. Narahara,et al.  Evaluation of epithelial cell proliferation rate in normal-appearing colonic mucosa as a high-risk marker for colorectal cancer. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[60]  G. Chejfec,et al.  High grade dysplasia still is not an indication for surgery in patients with Barrett's esophagus: An update , 1998 .

[61]  J. Lafitte,et al.  Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.

[62]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.